GlassScriptPhysician profile
Amanda H Fowler
NPI 1215224886
$12,719.25
in general payments reported to CMS, 2019-2025
23 companies · $2,284 in 2025
The $2,284 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,898 · 2020: $1,106 · 2021: $1,575 · 2022: $1,283 · 2023: $1,415 · 2024: $2,158 · 2025: $2,284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,724 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,723.73 |
| Education | $133.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,297.76 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Abbvie INC. | $3,131.61 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,197.80 | 2019-2025 | |
| Ucb, INC. | $826.42 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $824.82 | 2019-2025 | Tremfya |
| Pfizer INC. | $586.08 | 2019-2025 | |
| Glaxosmithkline, LLC. | $574.02 | 2019-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $433.42 | 2019-2025 | Orencia |
| Genentech USA, INC. | $382.28 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $279.67 | 2023-2025 | Acthar |
| Lilly USA, LLC | $217.92 | 2019-2025 | Taltz, Zepbound |
| Astrazeneca Pharmaceuticals LP | $149.81 | 2023-2025 | Saphnelo, Enhertu |
| Fresenius Kabi USA, LLC | $134.83 | 2023-2024 | Idacio |
| Celgene Corporation | $114.69 | 2019 | |
| Aurinia Pharma U.S., INC. | $113.24 | 2024 | Lupkynis |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $96.90 | 2025 | |
| Ani Pharmaceuticals, INC. | $92.26 | 2024-2025 | Purified Cortrophin Gel |
| Radius Health, INC. | $69.70 | 2019-2025 | |
| Organon LLC | $68.53 | 2023-2025 | Hadlima |
| Alexion Pharmaceuticals, INC. | $51.12 | 2024-2025 | Strensiq |
| Regeneron Healthcare Solutions, INC. | $40.99 | 2019 | |
| Sandoz INC. | $22.66 | 2024 | Hyrimoz |
| Boston Scientific Corporation | $12.72 | 2023 | Exalt Model D |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Fowler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.